Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies ; volume:14 ; number:1 ; day:10 ; month:6 ; year:2016 ; pages:1-12 ; date:12.2016
Journal of translational medicine ; 14, Heft 1 (10.6.2016), 1-12, 12.2016
- Urheber
-
Sun, Woo Young
- Beteiligte Personen und Organisationen
-
Lee, Yu Kyung
Koo, Ja Seung
SpringerLink (Online service)
- DOI
-
10.1186/s12967-016-0925-6
- URN
-
urn:nbn:de:1111-20160612466
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sun, Woo Young
- Lee, Yu Kyung
- Koo, Ja Seung
- SpringerLink (Online service)
Ähnliche Objekte (12)
Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients
The risk of PD-L1 expression misclassification in triple-negative breast cancer
Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort
PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer
Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC)
Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer
Diagnostic biopsy does not accurately reflect the PD-L1 expression in triple-negative breast cancer
Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer
Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study
Immunohistochemical Analysis of Foxp3+, CD4+, CD8+ Cell Infiltrates and PD-L1 in Oral Squamous Cell Carcinoma
Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients
The risk of PD-L1 expression misclassification in triple-negative breast cancer
Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort
PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer
Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC)
Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer
Diagnostic biopsy does not accurately reflect the PD-L1 expression in triple-negative breast cancer
Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer
Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study
Immunohistochemical Analysis of Foxp3+, CD4+, CD8+ Cell Infiltrates and PD-L1 in Oral Squamous Cell Carcinoma
Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients
The risk of PD-L1 expression misclassification in triple-negative breast cancer
Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort
PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer
Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC)
Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer
Diagnostic biopsy does not accurately reflect the PD-L1 expression in triple-negative breast cancer
Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer
Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study